Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01945775
Title A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Pfizer
Indications

breast carcinoma

Therapies

Gemcitabine

Capecitabine

Vinorelbine

Talazoparib

Eribulin

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.